SCHEMBL3368604

SCHEMBL3368604

N=C(N)c1ccc2oc3ccccc3c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPT P10636 3/20 0.55
KMT2A Q03164 3/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
KDM4E B2RXH2 2/20 0.55
HPGD P15428 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
TTR P02766 1/20 0.49
HTR2B P41595 1/20 0.48
F2 P00734 4/20 0.47
PLG P00747 2/20 0.47
PLAU P00749 2/20 0.47
KLK1 P06870 2/20 0.47
PRSS1 P07477 2/20 0.47
KLKB1 P03952 1/20 0.47
F10 P00742 1/20 0.46
PLAT P00750 1/20 0.46
AHR P35869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29213647 0.98 KMT2A (0.53) MEN1ALDH1A1MAPTKMT2ANPC1
SCHEMBL548255 0.91 F2 (0.53) ALDH1A1HPGDF2PLGPLAU
Hydrochloric Acid SCHEMBL7764733 0.89 F2 (0.51) ALDH1A1HPGDF2PLGPLAU
Hydrochloric Acid SCHEMBL2035460 0.89 F2 (0.51) ALDH1A1HPGDF2PLGPLAU
SCHEMBL21926432 0.84 ALOX5 (0.56) MEN1ALDH1A1MAPTKMT2ANPC1
SCHEMBL19561646 0.82 NPC1 (0.55) MEN1ALDH1A1MAPTKMT2ANPC1
SCHEMBL29886877 0.82 CHEK2 (0.59) MEN1ALDH1A1MAPTKMT2ANPC1
SCHEMBL6307220 0.82 CHEK2 (0.59) MEN1ALDH1A1MAPTKMT2ANPC1
SCHEMBL24741774 0.81 TTR (0.51) MEN1ALDH1A1MAPTKMT2ANPC1
SCHEMBL1819244 0.80 TTR (0.54) MEN1ALDH1A1MAPTKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 MEN1 3734/4885ALDH1A1 152/4885MAPT 4559/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK MEN1 3821/4885ALDH1A1 330/4885MAPT 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.